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Secondary infections with Streptococcus pneumoniae cause severe pneumonia and
enhance lethality during influenza epidemics and pandemics. Structural and functional
similarities with viral neuraminidase (NA) suggest that the highly prevalent pneumococcal
NAs, NanA and NanB, might contribute to this lethal synergism by supporting viral
replication and that dual acting NA inhibitors (NAIs) will disrupt it. To verify this
hypothesis, NanA and NanB were expressed in E. coli. After confirming their activity
in enzyme assays, in vitro models with influenza virus A/Jena/8178/09 (Jena/8178) and
the recombinant NanA or NanB (rNanA and rNanB) were established in A549 and MDCK
cells to mimic the role of these pneumococcal NAs during co-infection. Studies on the
influence of both NAs on viral receptor expression, spread, and yield revealed a distinct
effect of NanA and NanB on viral replication in these in vitro models. Both enzymes
were able to support Jena/8178 replication at certain concentrations. This synergism
was disrupted by the NAIs oseltamivir, DANA, katsumadain A, and artocarpin exerting
an inhibitory effect on viral NA and NanA. Interestingly, katsumadain A and artocarpin
inhibited rNanA and rNanB similarly. Zanamivir did not show activity. These results
demonstrate a key role of pneumococcal NAs in the lethal synergism with influenza
viruses and reveal opportunities for its effective disruption.
Keywords: pneumococci, secondary pneumococcal pneumonia, co-pathogenesis, pandemic influenza, enzyme
inhibition, antibacterial, antiviral, microbial communication
INTRODUCTION
The highly variable influenza A viruses evolve rapidly and cause epidemics and pandemics of
acute respiratory disease that are often characterized by high morbidity and mortality in humans
(Webster and Govorkova, 2014). Secondary Streptococcus (S.) pneumoniae infections increase
the severity and lethality in influenza virus-infected humans based on co-pathogenesis of both
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pathogens, also called lethal synergism as reviewed recently
(McCullers, 2014). “Despite advances in medical care and
numerous new antibiotics, the case fatality rate for complicated
bacterial pneumonia has not decreased appreciably since the
introduction of penicillin” (McCullers and English, 2008).
However, treatment with neuraminidase inhibitors (NAI)
reduces the risk of lower respiratory tract complications and
mortality (Muthuri et al., 2014; Dobson et al., 2015).
Due to the grave medical and economic impact of this lethal
synergism between influenza A viruses and S. pneumoniae, the
underlying viral and bacterial factors promoting it are under
intensive investigation. The lethal synergism requires influenza
virus infection prior to bacterial exposure (McCullers and Rehg,
2002). Therefore, several viral factors, in particular the viral
neuraminidase (NA) contributing to secondary infection with
S. pneumoniae by providing attachment receptors and nutrients
to the bacteria, were thoroughly investigated (McCullers and
Bartmess, 2003; Peltola and McCullers, 2004; McCullers, 2014;
Siegel et al., 2014). In mice, NAI abolished the viral support for
bacterial adherence and improved the outcome of S. pneumoniae
induced secondary pneumonia (McCullers and Bartmess, 2003;
McCullers, 2004; Peltola and McCullers, 2004; Tanaka et al.,
2014).
In contrast, the role of pneumococcal virulence factors was
less studied until now. Rebound of virus titers was detected after
co-infection with S. pneumoniae in vivo due to an enhanced
viral release from infected cells (McCullers and Rehg, 2002;
Smith et al., 2013). It implied the strengthened NA activity from
pneumococci promoted the virus release. In addition, rescue
of influenza virus release by S. pneumoniae in vitro from the
inhibition of NAI zanamivir (Nishikawa et al., 2012) further
indicated pneumococcal NAs empowered the observed virus
titers rebound in vivo.
Streptococcus pneumoniae expresses three distinct NAs: NanA,
NanB, and NanC (Pettigrew et al., 2006; Xu et al., 2011;
Walther et al., 2015). The most active and highly expressed
NanA (Berry et al., 1996; Manco et al., 2006) was detected
in all S. pneumoniae strains and has a conserved catalytic site
(King et al., 2005; Pettigrew et al., 2006; Walther et al., 2015).
NanA hydrolyzes α2,3-, α2,6-, and α2,8-sialyllactose to release
N-acetyl-neuraminic acid (Neu5Ac; Xu et al., 2011). It supports
colonization and sepsis in vivo (Orihuela et al., 2004; Manco et al.,
2006; Song et al., 2008). Its impact on biofilm formation is in
discussion (King et al., 2004; Oggioni et al., 2006; Parker et al.,
2009; Trappetti et al., 2009; Walther et al., 2015). NanB, detected
in most but not all S. pneumoniae strains (Pettigrew et al., 2006;
Walther et al., 2015), represents a trans-sialidase transferring 2,7-
anhydro-Neu5Ac from α2,3-sialosides to other glycoconjugates
(Gut et al., 2008; Xu et al., 2008, 2011) and contributes to
deglycosylation of sialic acids (SA) in vitro (Burnaugh et al.,
2008) and in vivo (Tong et al., 2001; Siegel et al., 2014). NanB
deficient strains are unable to colonize the nasopharynx or to
cause sepsis (Manco et al., 2006). NanB is highly expressed in
biofilm (Manco et al., 2006; Oggioni et al., 2006). Its different
substrate specificity (Gut et al., 2008; Xu et al., 2011) together
with slightly different pH optima (pH 5.5-6.5 for NanA, pH 5.0–
5.5 for NanB; Hayre et al., 2012) suggests a distinct role of NanB
in bacterial pathogenicity and in the synergism between influenza
viruses and S. pneumoniae. In contrast to NanA and NanB, NanC
is rarely expressed (Pettigrew et al., 2006; Walther et al., 2015).
Interestingly, it was suggested to regulate the activity of NanA
via producing 2-deoxy-2,3-didehydro-N-acetylneuraminic acid
(DANA), a known NAI (Xu et al., 2011; Owen et al., 2015).
Despite the distinct quaternary structures of viral and
pneumococcal NAs (viral NA as tetramer and bacterial NAs
as monomer), their active sites show close similarities (von
Grafenstein et al., 2015), suggesting that S. pneumoniae could
be targeted by NAIs. However, the viral NAI zanamivir does not
bind efficiently to the active site of NanA and NanB because the
residues involved in key interactions (e.g., Glu119 and Glu227 in
the viral NA: N2 numbering) are not conserved in S. pneumoniae
NAs (Gut et al., 2011). In contrast, oseltamivir competitively
inhibits NanA (Gut et al., 2011; Walther et al., 2015). Two
natural compounds, katsumadain A and the isoprenylated
flavone artocarpin, also inhibited pneumococcal NA activity
(Richter et al., 2015; Walther et al., 2015). Hence, the dual acting
NAIs (active against both viral and bacterial NA) might have
the potential to combat the lethal synergism between influenza
virus and secondary pneumococcal infection by targeting the
interaction between both pathogens.
The present study aims (i) to verify the impact of
pneumococcal NanA and NanB on influenza virus replication
and (ii) to evaluate the potential of dual acting NAI via
in vitro influenza virus-S. pneumoniae co-infection model. We
expressed NanA or NanB in E. coli to achieve recombinant
NAs (rNanA or rNanB) and established cell-based models with
the A(H1N1)pdm09 isolate A/Jena/8178/09 (Jena/8178) and the
recombinant NAs to mimic the co-infection with S. pneumoniae.
We used the models to evaluate the effect of pneumococcal NAs
on the spread and yield of the virus, and the availability of
viral receptors. Furthermore, the efficacy of NAIs was studied
under experimental conditions mimicking the lethal synergism
of influenza virus and S. pneumoniae.
MATERIALS AND METHODS
Compounds
Oseltamivir carboxylate (GS4071; GlaxoSmithKline, Uxbridge,
UK), zanamivir (GG167; F. Hoffmann-La Roche AG, Basel,
Switzerland), and N-acetyl-2,3-dehydro-2-deoxyneuraminic
acid (DANA; Sigma–Aldrich GmbH, Taufkirchen, Germany)
were dissolved in bi-distillated water. Artocarpin (Quality
Phytochemicals LLC, East Brunswick, NJ, USA) and katsumadain
A, previously isolated from the seeds of Alpinia katsumadai
Hayata (Grienke et al., 2010) were dissolved in DMSO. Except
for DANA (stored at –20◦C), compound stocks (10 mM) were
stored at 4◦C until use.
Cells
Human lung carcinoma cells (A549; Institute of Molecular
Virology, University of Münster, Germany) were propagated in
Dulbecco’s Modified Eagle Medium (DMEM; Lonza Group Ltd,
Basel, Switzerland) supplemented with 10% fetal calve serum
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(PAA Laboratories GmbH, Cölbe, Germany). Madin–Darby
canine kidney (MDCK) cells (Friedrich-Loeﬄer Institute, Riems,
Germany) were grown in Eagle’s minimum essential medium
(EMEM; Lonza Group Ltd) supplemented with 10% fetal
bovine serum (Sigma–Aldrich GmbH), and 2 mM L-glutamine
(Lonza Group Ltd), 10% non-essential amino acids (Lonza
Group Ltd), 1 mM sodium pyruvate (Lonza Group Ltd.).
Cells were maintained in a humidified incubator at 37◦C with
5% CO2.
Test medium used for virus propagation and in vitro
studies with virus was serum-free but contained 0.25 µg/mL
(A549 cells) or 2 µg/mL (MDCK cells) trypsin (Sigma–
Aldrich GmbH) and 1.3% sodium bicarbonate (Lonza Group
Ltd.).
Virus
The stock of the A(H1N1)pdm09 influenza virus isolate
A/Jena/8178/09 (Jena/8178) was prepared in MDCK cells,
aliquoted, and stored at –80◦C until use.
Expression of rNanA and rNanB
The expression and purification of nanA of S. pneumoniae
DSM20566 has been described previously (Walther et al., 2015).
The nanB from the same strain was amplified with the primers:
nanB_NcoI_fw (5′-GGAAAACCATGGATAAAAGAGG-3′) and
nanB_XhoI_rv (5′-TTCTCTCGAGTTTTGTTAAATC-3′). After
the double-digestion with NcoI and XhoI, the ∼2.1 kb PCR
product was cloned into E. coli expression vector pET-28a.
The obtained plasmid pTNB20566 encodes a C-terminal 6xHis-
tagged NanB in size of 699 amino acid residues. Expression and
purification of NanB was done as described for NanA (Walther
et al., 2015).
Analysis of Pneumococcal NA Activity
Activity of 10-fold dilutions (1:1,000 to 1:100,000) of rNanA
and rNanB was determined with a fluorescence-based NA assay
(FL assay) using the substrate 2-(4-methylumbelliferyl)-α-D-N-
acetylneuraminic acid sodium salt hydrate (MUNANA, Sigma–
Aldrich GmbH) as published (Richter et al., 2015). The activity of
rNanB was additionally tested at pH 5. Relative FL units (RFU)
were read using the microplate reader FLUOstar Omega (BMG
Labtech GmbH, Ortenberg, Germany) and converted to 4-MU
concentration (Sigma–Aldrich GmbH) according to the 4-MU
standard curve (Supplementary Figure 1). Velocity (µM/min)
and Km value (µM) for rNanA and rNanB were determined
using eight MUNANA concentrations (3.13 to 400 µM) at pH
6.5. After 5 min the reaction was stopped, RFU were measured
and converted to 4-MU concentrations according to the 4-
MU standard curve. The Enzyme Kinetics Module of SigmaPlot
12.0 (Systat Software, San Jose, CA, USA) was applied to fit
the data to the Michaelis–Menten equation using non-linear
regression.
Neuraminidase activity of both NAs was further confirmed
based on hemagglutination of NA-treated human erythrocytes in
the presence of peanut lectin (HA assay) as described recently
(Richter et al., 2015; Walther et al., 2015).
NA Inhibition
The NAI susceptibility of rNanA and rNanB was evaluated with
FL assay (rNanA and rNanB diluted 1:10,000 in FL buffer; pH
6.5) and HA assay as published recently (Richter et al., 2015) with
slight modification of the HA assay. For stability reasons, rNanA
and rNanB were diluted 1:5,000 in phosphate buffered saline
(PBS) containing 100 µg/mL bovine serum albumin and stored
at –20◦C until use. The incubation period of the recombinant
proteins with the human erythrocytes was only 1 h. At least three
individual experiments were performed.
NAI susceptibility of Jena/8178 NA was proved in the FL assay.
Effects of Recombinant NAs on Viral
Replication In Vitro
Confluent MDCK and A549 cells were mock-infected with test
medium or infected with Jena/8178 (0.1 TCID50/cell) for 1 h
(37◦C; 5% CO2). After three washing steps with test medium,
test medium or various rNanA or rNanB dilutions (1:100 to
1:1,000,000) were added. After 48 h at 37◦C the supernatant
was taken and stored at –20◦C until plaque titer determination
(virus yield analysis). The remaining cells were fixed with ice-cold
methanol for 20 min and stored after washing with PBS in PBS at
4◦C until immunocytochemical staining (virus spread analysis).
Virus Yield and Spread Analysis
To determine the virus yield in collected supernatants, plaque
assays were conducted on confluent MDCK cells grown in 12-
well tissue culture plates (Greiner Bio-One GmbH). Briefly, after
virus adsorption (37◦C; 1 h), inoculum was replaced by 1 mL test
medium containing also 0.4% agarose and 50 mM magnesium
chloride (VEB Laborchemikalien, Apolda, Germany). After 48 h
of incubation at 37◦C, cells were fixed and stained with a solution
of 0.4% crystal violet in a mixture of formalin (3% v/v) and
ethanol (1.67% v/v) in water overnight. Plaques were counted
over a light box after removal of the agar overlay.
Virus spread was analyzed by detecting viral nucleoprotein
with a monoclonal antibody (Acris GmbH, Hiddenhausen,
Germany) by immunocytochemical staining according to the
manufacturers protocol (DAKO, Hamburg, Germany; Bauer
et al., 2007).
Effects of Recombinant NAs on
Inhibition of Virus Replication by NAI
The inhibitory effect of the NAI on Jena/8178 (inhibition of virus
yield and spread) was determined in absence and presence of
rNanA or rNanB in A549 cells. NA dilutions were used that (i)
did not reduce the amount of SA α2,3-Galactose (Gal) and SA
α2,6-Gal but, (ii) significantly increased virus yield and spread.
Detection of Sialic Acid (SA)
α2,3-Galactose (Gal) and SA α2,6-Gal
Confluent A549 or MDCK cells were incubated for 48 h at 37◦C
with 10-fold diluted NanA or NanB. After methanol fixation the
effect of pneumococcal NAs on cell surface SA was investigated by
immunocytochemical staining with a DIG glycan differentiation
kit (F. Hoffmann-La Roche AG) as reported (Seidel et al.,
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2014). DIG-labeled Sambucus nigra agglutinin (SNA) or Maackia
amurensis agglutinin (MAA) recognizes SA α2,6-Gal and SA
α2,3-Gal, respectively. The red staining chromogenic solution
of the DAKO REAL Detection System APAAP, Mouse (DAKO,
Hamburg, Germany), was used for SNA and MAA detection.
Molecular Modeling
Homology models of Jena/8178 and NanA and NanB of
S. pneumoniae DSM20566 were generated with Swiss-Model
(Biasini et al., 2014) using PDB 4b7q, 2vvz and 2jkb as templates,
respectively. Oseltamivir and zanamivir were extracted from
aligned co-crystallized structures (2hu0 and 4b7q) and inserted
into the homology models. Residue numbering of the template
structures was preserved. Graphics were rendered using PyMol
version 0.99 (DeLano Scientific LLC, 2006).
Statistical Analysis
Means and standard deviations were analyzed using Microsoft
Excel 2010. Significant differences in the co-incubation assay
were calculated in SPSS Statistics Version 22 with non-parametric
Wilcoxon–Mann–Whitney test.
RESULTS
Effects of NanA and NanB on Virus
Replication
Streptococcus pneumoniae induced cytopathic effects in A549 and
MDCK cells susceptible and permissive for Jena/8178, even at low
multiplicities of infection (MOI; results not shown). Therefore,
we added recombinant protein rNanA and rNanB at different
concentrations to Jena/8178-infected A549 and MDCK cells at
the time of viral infection to probe the role of pneumococcal NAs
during the co-infection.
Both rNanA and rNanB were expressed in E. coli and their
activity was confirmed by the FL assay at pH 5 (for rNanB
only) and pH 6.5 (for both rNanA and rNanB). The Km value
of rNanA (39.70 ± 5.81 µM) differed at least by one order of
magnitude to that of rNanB (684.03 ± 162.76 µM), indicating
a much stronger affinity of rNanA to MUNANA under these
assay conditions (Supplementary Figure 2). Activities of both
recombinant S. pneumoniae NAs were further confirmed under
more physiological conditions in a hemagglutination assay (HA
assay; Richter et al., 2015). In this HA assay, the removal of
terminal SA at the surface of erythrocytes by rNanA and rNanB
allowed the hemagglutination via peanut lectin as the approval of
enzyme activity (results not shown).
Thereafter, we evaluated the effect of both S. pneumoniae
NAs on Jena/8178 replication in A549 and MDCK cells. The
applied MOI of 0.1 TCID50/cell resulted in only few infected
cells during the first cycle of viral replication (Supplementary
Figure 3). To study the influence of rNanA and rNanB on viral
replication, different 10-fold enzyme dilutions were added at
the time of virus inoculation. Forty-eight hours after infection,
immunocytochemical staining was used to visualize the virus
spread in NA-treated and untreated cells. In parallel, the virus
yield of the supernatant was determined by plaque assay.
Intriguingly, less diluted rNanA and rNanB (dilutions less than
1:1,000 and 1:100 for rNanA and for rNanB, respectively)
hampered the spread of the virus in A549 cells (Figures 1A,B). In
contrast, higher dilutions of rNAs (dilutions more than 1:10,000
and 1:1,000 for rNanA and for rNanB, respectively) promoted
virus spread. Similar results were obtained with MDCK cells
(Supplementary Figure 4). The yield of virus under the same
experiment conditions was in good agreement with these results.
The addition of less diluted pneumococcal NA to Jena/8178-
infected A549 cells led to a decrease yield of virus, and vice versa
(Table 1). The 1:1,000,000 dilutions of both NAs had no more
FIGURE 1 | Spread of A(H1N1)pdm09 strain A/Jena/8178/09 (Jena/8178) in the absence and the presence of different dilutions of recombinant NanA
and NanB. The effect of NanA (A) and NanB (B) on virus spread in A549 cells was analyzed by immunocytochemical staining of viral nucleoprotein (shown in red)
48 h after infection with Jena/8178 at MOI of 0.1 TCID50/cell.
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TABLE 1 | Effect of recombinant NanA (rNanA) and NanB (rNanB) on virus
yield in A549 cells.
Dilution of NAs Percentage of virus yield in the presence of
rNanAa rNanBa
1:100 2.8 ± 4.6 15.5 ± 4.5
1:1,000 12.2 ± 5.7 204.8 ± 77.5
1:10,000 234.4 ± 70.5 202.5 ± 107.3
1:100,000 171.7 ± 37.1 186.1 ± 34.5
1:1,000,000 103.2 ± 31.7 114.8 ± 47.4
aThe plaque titer of influenza virus A/Jena/8178/09 reached in A549 cells (48 h
after infection) was determined in MDCK cells. Plaque titer without pneumococcal
neuraminidases was set to 100% virus yield and used to calculate the percentage
of virus yield in presence of rNanA and rNanB. Mean and standard deviations of at
least two assays with two replicates are shown.
effect on virus growth. These results clearly demonstrate that
at certain concentrations both NanA and NanB are capable of
enhancing the replication of influenza virus.
NanA and NanB Diminish Virus Receptor
Availability
The reduced viral spread and yield in the presence of high
amounts of pneumococcal NAs suggests a removal of viral
receptors by these enzymes. SA linked via α2,3 or α2,6 to
galactose (SA α2,3-Gal and SA α2,6-Gal) function as receptors
for influenza viruses and facilitate their attachment to host cells,
the initial step in the viral replication cycle (Nicholls et al.,
2013). To investigate the influence of rNanA and rNanB on
virus receptors, we used the lectins MAA and SNA, respectively,
to detect SAα2-3Gal and SAα2-6Gal on the cell surface. Both
receptors of influenza A virus could be identified on A549
(Figures 2A,B) and MDCK cells (Supplementary Figure 5),
which is consistent with previously published data (Kumari et al.,
2007; Bauer et al., 2012; Seidel et al., 2014). SA α2,3-Gal and
SA α2,6-Gal were strikingly reduced by rNanA at 1:100 and
1:1,000 dilutions when compared to the untreated cell control
(Figures 2A,B). A decrease of SA α2,3 was induced by 1:100 and
1:1,000 diluted rNanB, whereas no obvious changes at SAα2,6
levels were observed (Figures 2A,B). No apparent reduction of
the receptors was observed after the NA treatment with dilutions
larger than 1:10,000. Similar effects were observed in MDCK cells
(Supplementary Figure 5).
Katsumadain A and Artocarpin Target
NanA and NanB
Recently, we described a HA assay with highly robust readout for
comparing the efficiency of NAIs against viral and bacterial NAs
FIGURE 2 | Influence of recombinant NanA and NanB on expression of SA on the surface of A549 cells. Cells were treated with different neuraminidase
dilutions for 48 h. The lectins MAA (A) and SNA (B) were used to detect SAα2-3Gal and SAα2-6Gal, respectively, by immunocytochemical staining. Control (Co) was
stained without using lectins.
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of the protein precipitate of S. pneumoniae DSM20566 (Richter
et al., 2015). S. pneumoniae DSM20566 expresses NanA and
NanB (Walther et al., 2015). Here we extended these studies
and compared the NAI activity against rNanA and rNanB of
S. pneumoniae DSM20566. In addition to oseltamivir, zanamivir
and DANA (used as control NAI), the inhibitory potentials of
katsumadain A and artocarpin were studied.
In the HA assay, oseltamivir, DANA, katsumadain A, and
artocarpin but, not zanamivir inhibited rNanA (Table 2).
Compared to rNanA, rNanB was approximately 10-times less
susceptible to oseltamivir. Zanamivir and DANA were inactive.
Interestingly, katsumadain A and artocarpin inhibited both NAs
with similar efficiency. In contrast to rNanA, rNanB was not
susceptible to artocarpin in the FL assay (Table 2). Apart from
this discrepancy, the FL assay data confirmed the HA assay
results. Due to the self-fluorescence of katsumadain A (Richter
et al., 2015), the compound could not be tested in the FL assay.
Targeting the Interaction of S.
pneumoniae NAs with Influenza Virus by
NAI
A dilution of 1:10,000 of both pneumococcal NAs supported
Jena/8178 replication (Table 1 and Figure 1). Therefore, this
dilution was selected to study the effect of NAIs on Jena/8178
spread and yield in the presence and absence of rNanA or
rNanB. The NA of Jena/8178 has been proved to be susceptible
to all tested NAIs (Supplementary Table 1). In the absence of
pneumococcal NAs, NAIs reduced Jena/8178 spread and yield in
A549 cells (Figure 3, Supplementary Table 2).
The antiviral effect of zanamivir was abolished in the presence
of rNanA (Figures 3B,D, Supplementary Table 2) because rNanA
was insensitive to zanamivir (Table 2) but able to cleave SA α2,3-
Gal as well as SA α2,6-Gal like the viral NA (Figure 2). Thus,
rNanA was fully capable to replace the function of viral NA
when it was blocked by zanamivir. Both spread and yield of the
virus were inhibited by oseltamivir (1 µM), DANA, katsumadain
A, and artocarpin despite the presence of NanA. These NAIs
block rNanA activity (Table 2). However, at lower concentration
of 0.1 µM, the antiviral effect of oseltamivir was abrogated by
rNanA (Supplementary Table 2).
Independently from their inhibitory activity against rNanB
(Table 2), all tested NAIs were active in the presence of rNanB
and reduced the spread and yield of virus (Figures 3C,D,
Supplementary Table 2). Thus, the presence of rNanB did
not affect NAI efficacy against Jena/8178. At first glance
this was a surprising result. However, in contrast to viral
NA, which predominantly cleaves SA α2,6-Gal, NanB only
cleaves SA α2,3-Gal (Gut et al., 2008; Xu et al., 2008, 2011).
Therefore, NanB cannot replace the function of the inhibited
viral NA.
DISCUSSION
In the present study, we demonstrate the critical role of
S. pneumoniae NanA and NanB for influenza virus replication in
a newly established in vitro model. NAIs acting against viral and
bacterial NAs were shown to disrupt the observed S. pneumoniae
NA-based synergism in this model.
High amounts of rNanA and rNanB removed the SA from
A549 and MDCK cell surfaces that are used as viral receptors
thereby compromising Jena/8178 replication. Influenza virus
A(H1N1)pdm09 isolates preferentially attach to SA α2,6-Gal
(Stevens et al., 2006; Childs et al., 2009; Seidel et al., 2014).
Therefore, removal of SA α2,6-Gal and/or SA α2,3-Gal by
pneumococcal NAs (Xu et al., 2011) impairs or even blocks
the replication of Jena/8178. Notably, removal of SA-containing
receptors from respiratory epithelial cells is also the mechanism
of action of the investigational antiviral drug DAS181 (Fludase;
Nicholls et al., 2013). The obtained results help to explain
why synergism only occurs “when the viral infection precedes
bacterial exposure and no effect – or even protection – occurs
when the order of challenge is reversed” (McCullers, 2014).
An opposed effect was observed in A549 cells infected with
Jena/8178 when rNanA or rNanB dilutions were used that do
not lead to a significant cleavage of SA from the receptors.
Under these experimental conditions the pneumococcal NAs
effectively enhanced the cleavage function for viral release,
therefore promoted the viral replication. It demonstrated that
both rNanA and rNanB contributed to the rebound of virus titers
observed during the secondary pneumococcal infection in vivo
TABLE 2 | Inhibition of recombinant NanA (rNanA) and NanB (rNanB) by neuraminidase inhibitors (NAIs).
NAI Inhibitory Concentration of NAIs in µM against
rNanA rNanB
FL assaya HA assayb FL assaya HA assayb
Oseltamivir 2.9 ± 1.0 3.2 ± 0.0 76.8 ± 27.4 31.6 ± 0.0
Zanamivir Not active Not active Not active Not active
DANA 17.7 ± 2.0 100.0 ± 0.0 Not active Not active
Katsumadain A Not evaluablec 3.2 ± 0.0 Not evaluablec 5.4 ± 4.0
Artocarpin 10.0 ± 6.3 10.0 ± 0.0 Not active 10.0 ± 0.0
aMean 50% inhibitory concentration (IC50) and standard deviation determined in FL assay in at least three independent assays. The maximum tested concentration
was 100 µM. bMean minimal inhibitory concentration (MIC) and standard deviation determined in HA assay in at least three independent assays. The maximum tested
concentration was 100 µM. cNot evaluable due to self-fluorescence of the compound (Richter et al., 2015).
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FIGURE 3 | Inhibition of replication of A(H1N1)pdm09 strain A/Jena/8178/09 (Jena/8178) by neuraminidase inhibitors (NAIs). A549 cells infected with
Jena/8178 (MOI of 0.1 TCID50/cells) were treated with oseltamivir, zanamivir, DANA, artocarpin, and katsumadain A in absence of pneumococcal NAs (A), presence
of rNanA (B) or presence of rNanB (C). Virus-infected cells were detected by immunocytochemical staining of viral nucleoprotein (shown in red) 48 h after infection to
visualize the inhibitor effect on virus spread. To analyze the effect of NAIs on virus yield (D), virus titers in pfu/mL were determined with plaque assay 48 h after
infection. Virus control titer was set to 100% and inhibition of the control titer by NAIs in % was calculated. Experiments were performed at least three times, and one
representative assay is exemplarily shown. Significant values were calculated with non-parametric Wilcoxon–Mann–Whitney test (∗p < 0.5, ∗∗p < 0.1).
FIGURE 4 | Computational models of the binding of oseltamivir (carbons blue) and zanamivir (carbons green) to A/Jena/8178/09, NanA and NanB.
While both inhibitors fit well to the viral NA (A), steric clashes (marked by a red X) of zanamivir with I416 in NanA (B) and the equivalent in NanB, I326, and T539 (C)
are apparent. These are likely the cause for the observed inactivity of zanamivir on both bacterial NAs.
(McCullers and Rehg, 2002; Smith et al., 2013). However, the
effect will depend on the receptor specificity of a given virus.
The distinct role of NanA and NanB in the co-pathogenesis
of influenza virus and S. pneumoniae are also apparent from
the data of inhibition assays with NAIs. As published for NanA
(Hayre et al., 2012; Nishikawa et al., 2012; Richter et al., 2015;
Walther et al., 2015) and confirmed by the enzyme inhibition
assays in the present study, zanamivir is unable to inhibit the
bacterial NAs activity till 100 µM. When co-incubating the virus,
zanamivir and rNanA, “bacterial neuraminidases functioned as
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the predominant NA when viral NA was inhibited to promote the
spread of infection” (Nishikawa et al., 2012). The same effect was
observed for the low oseltamivir concentration (0.1 µM) that is
ineffective against rNanA (Richter et al., 2015). In contrast, virus
yield and spread remain reduced in the presence of NanB, leading
to the conclusion that NanB cannot replace the NA function of
Jena/8178 as NanA does. Unlike NanA, which can cleave both
SA linkages, NanB has limited activity to cleave only SA α2,3-Gal
(Gut et al., 2008; Xu et al., 2008, 2011). For this reason, NanB
can only partially replace the cleavage function of Jena/8178
NA for an effective viral release and spread. In agreement with
the fact that NanA is susceptible to oseltamivir, the addition
of NanA did not rescue the viral spread. Due to the structural
differences within the active sites of viral and pneumococcal NAs,
the inhibition efficiency of oseltamivir toward NanA is markedly
lower (Gut et al., 2011). We modeled the three NAs in question
with oseltamivir and zanamivir bound (Figure 4). These models
are in agreement with the collected in vitro data and are able to
explain the observed inhibitory activity. It was found that steric
clashes are the primary reason for inactivity on one or several of
these structurally related enzymes.
In contrast to oseltamivir and DANA, katsumadain A and
artocarpin were effective against NanA and NanB in the HA
assay and inhibited the viral NA as well, which underlines our
previous finding about the extended interaction of these natural
compounds with NAs (Grienke et al., 2010; Kirchmair et al., 2011;
Richter et al., 2015; Walther et al., 2015). They also inhibited viral
replication. Moreover, artocarpin exerted antibacterial activity
(Walther et al., 2015). Therefore, we suggest that its structure
could provide the base for the search of compounds with stronger
activity against both influenza viruses and S. pneumoniae.
In summary, our findings suggest distinct roles for NanA and
NanB in the lethal synergism of A(H1N1)pdm09 strains and
S. pneumoniae, as well as for influenza treatment with NAIs.
It should be considered that their effect might depend on the
virus strain due to the differences in the use of SAα2,6-Gal
and/or SAα2,3-Gal modified receptors (Kumari et al., 2007). For
example, the impact of NanB on avian or avian-like swine viruses
that preferentially bind to SAα2,3-Gal might be much stronger
(Nicholls et al., 2007; Bauer et al., 2012). The effect of viral
NAIs that are unable to inhibit the pneumococcal NanA can
be diminished. In consequence, only NAIs targeting viral and
pneumococcal NanA as well NanB will help to prevent the lethal
synergism.
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